SmallCapSentinel.com Releases Report for Investors of Medical Device Companies SENO, STXS, EVVV, ANGO, THOR, and CPTS
10 Junio 2009 - 8:35AM
PR Newswire (US)
LAS VEGAS, June 10 /PRNewswire/ -- SmallCapSentinel.com announces
the availability of the report "A Growing Body of Evidence" related
to the medical device industry featuring SenoRx, Inc. (NasdaqGM:
SENO) and of interest to investors of Stereotaxis Inc. (NasdaqGM:
STXS), ev3 Inc. (NasdaqGS: EVVV), AngioDynamics Inc. (NasdaqGS:
ANGO), Thoratec Corp. (NasdaqGS: THOR) and Conceptus Inc.
(NasdaqGM: CPTS). To read the article "A Growing Body of Evidence"
visit: http://www.smallcapsentinel.com/SENO6-7 From the report:
SenoRx, Inc. believes that a breast cancer patient treated with its
Contura(TM) Multi-Lumen Balloon (MLB) receives a more targeted dose
of radiation while minimizing radiation to healthy surrounding
tissue such as the skin and ribs than those treated with whole
breast irradiation or with a single-lumen balloon. A growing and
compelling body of scientific data suggests SenoRx is right. Over
the past few months data has been rolling in from experts and
opinion leaders, research partners and clinical sites. A consensus
is forming and the future for Contura MLB (and SenoRx) seems
brighter than ever. For an Integrity Media profile of SenoRx please
visit: http://www.integrityir.com/SENO To view the related article,
"Innovation and Speed to Market" visit:
http://integrityir.com/SENOSCS1 Register to receive these reports
directly at: http://www.smallcapsentinel.com/register Statements
herein may contain forward-looking statements and are subject to
significant risks and uncertainties affecting results. Small Cap
Sentinel is property of Integrity Media Inc. (IMI). IMI provides no
assurance as to the subject company's plans or ability to effect
proposed actions and cannot project capabilities, intent,
resources, or experience. The subject companies haven't always
approved the statements made in this report. This report is neither
a solicitation to buy nor offer to sell securities and is for
information purposes only and shouldn't be used as basis for
investment decisions. IMI isn't an investment advisor, analyst or
licensed broker dealer and this report isn't investment advice. IMI
has been paid thirty-thousand dollars by SenoRx for this report and
other services to be performed over the remainder of the calendar
year. Paid reports constitute a conflict of interest as to IMI's
ability to remain objective in communication regarding subject
companies. S.Convery CRD #2495267. Contact: Kurt Divich, Editor
Integrity Media Inc. 702-396-1000 DATASOURCE: Integrity Media
CONTACT: Kurt Divich, Editor of Integrity Media Inc.,
+1-702-396-1000 Web Site: http://www.integrityir.com/
Copyright